[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100371799":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":25,"locations":35,"responsibleParty":49,"collaborators":25,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":25,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":25,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":72,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence AB: TAK-906 25 mg + TAK-906 25 mg and Rifampin 600 mg","EXPERIMENTAL","TAK-906 25 milligram (mg) (Treatment A), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.",[13,14],"Drug: TAK-906","Drug: Rifampin",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence BA: TAK-906 25 mg and Rifampin 600 mg + TAK-906 25 mg","Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg (Treatment A), capsule, orally, once on Day 1 of Study Period 2.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","TAK-906","TAK-906 capsule.",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Rifampin","Rifampin infusion.",[9,16],[31],{"name":32,"affiliation":33,"role":34},"Medical Director","Millennium Pharmaceuticals, Inc.","STUDY_DIRECTOR",[36],{"facility":37,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":25},"Celerion","Lincoln","Nebraska","68502","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-96.66696,40.8,{"lat":47,"lon":46},{"type":50,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100371799","phase-1-a-study-to-evaluate-the-effect-of-single-dose-intravenous-rifampin-as-a-prototypic-inhibitor-of-organic-anion-transporting-polypeptide-oatp-1b1-and-oatp1b3-on-the-single-dose-pharmacokinetics-pk-of-oral-tak-906-in-healthy-adult-participants-100371799",true,"NCT04121078","A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants","A Phase 1, Open-Label, Randomized, Two-Way Crossover Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of OATP1B1 and OATP1B3 on the Single-Dose Pharmacokinetics of Oral TAK-906 in Healthy Adult Subjects","Inclusion Criteria:\n\n1. Continuous non smoker who has not used nicotine containing products for at least 3 months prior to the first dosing and throughout the study, based on screening urine cotinine test.\n2. Body Mass Index (BMI) greater than or equal to (\\>=) 18.0 and less than or equal to (\\\u003C=) 30.0 kilogram per square meter (kg\u002F m\\^2) at screening.\n3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the investigator or designee.\n\nExclusion Criteria:\n\n1. Positive urine drug or alcohol results at screening and each check in.\n2. Positive urine cotinine at screening.\n3. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).\n4. QT interval with Fridericia's correction (QTcF) interval is \\>450 millisecond (msec) or ECG findings are deemed abnormal with clinical significance by the investigator or designee at screening.\n5. Estimated creatinine clearance \\\u003C90 milliliter per minute (mL\u002Fmin) at screening.\n6. Has been on a diet incompatible with the on-study diet, in the opinion of the investigator or designee, within the 30 days prior to the first dosing and throughout the study.\n7. Donation of blood or significant blood loss (example, approximately 500 milliliter \\[mL\\]) within 56 days prior to the first dosing.\n8. Plasma donation within 7 days prior to the first dosing.","ALL","19 Years","55 Years",{"count":62,"type":63},12,"ACTUAL","INTERVENTIONAL",[66],"PHASE1","The purpose of this study is to evaluate the effect of single dose intravenous rifampin on the single-dose PK of orally administered TAK-906.",[69],"Healthy Volunteers",[71],"Drug Therapy","COMPLETED","2020-11-13",{"date":75,"type":63},"2020-12-09",{"date":77,"type":63},"2019-10-15",{"date":79,"type":63},"2019-11-16",{"name":33,"class":6},1]